FOSTERING NEXT GENERATION OF LIVING DRUGS
Center for IPS cell therapy
Our first Mission is to build the French National Bank of GMP IPSC
The reason why of a national bank is to :
- minimise cost, logistics, redundancy & to increase the chance to finding rare HLA-matched donors
- Guarantee high standard of quality control & ethical applications
A French center for IPS cell based therapies
CITHERA is developing the national bank of clinical grade pluripotent stem cells and new cellular biomedicines to fight cancer. This Center of the University of Paris Saclay, Inserm and the University of Evry at Genopole, is directed by Professor Annelise Bennaceur Griscelli and it is attached to the INSERM UA09 Unit ‘Malignant and therapeutic stem cell models’ under the direction of Professor Ali Turhan in Villejuif, near Paris . CITHERA was awarded as Industrial integrator by the « Grand Défi » from the Government recovery plan innovation council.
CITHERA is the platform that coordinates the INGESTEM infrastructure of the medical and industrial exploitation sector of IPSC stem cells and its mission is to build the clinical grade iPSC bank with the know-how acquired since the derivation of the first ESC lines in 2006 then IPSC in 2008.
CiTHERA, founding member of the MAGENTA industrial integrator
CiTHERA, lauréat du Grand Défi « Biomédicaments » du gouvernement, dans le cadre de son projet SOFTCELL
Communiqué presse - Laureats grand defis biomedicaments - Fevrier 2022
AACR Annual Meeting 2022 - April 8 - 13, 2022 Ernest N. Morial Convention Center - New Orleans, Louisiana https://www.aacr.org/meeting/aacr-annual-meeting-2022/
The Global Stem Cell Event - San Francisco, USA - https://www.isscr.org/meetings-events/annual-meetings/isscr-annual-meeting-2022
INSERM U1310 publishes a review on IPSC derived organoids https://pubmed.ncbi.nlm.nih.gov/34722569/
Novel immunotherapy potential of iPSC: INSERM U1310 reports the major potential of IPSC as cancer vaccines read the article here : https://pubmed.ncbi.nlm.nih.gov/34957134/
Potential of iPSC-derived Mesenchymal stem cells for therapy of COVID-19-associated organ failure reported by INSERM 1310
Potential of iPSC-derived Mesenchymal stem cells for therapy of COVID-19-associated organ failure reported by INSERM 1310 read the article here : https://pubmed.ncbi.nlm.nih.gov/33237619/
CITHERA and INSERM U1310 are part of the Horizon Europe call: HORIZON-HLTH-TOOL-2021-06- 02: Next generation advanced therapies to treat prevalent and high burden diseases with unmet needs
After evaluation by the INSERM scientific committee CSS2 (Cancer), INSERM U935 has been renewed as a monothematic Inserm Unit UMRS 1310 under the direction of Pr. Ali Turhan. The Unit, in close collaboration with CITHERA is developing cancer and leukemia models for...
CiTHERA, lauréat du Grand Défi « Biomédicaments » du gouvernement, dans le cadre de son projet SOFTCELL. Découvrez l'article ici...
New label for INSERM U935 /UA9: After evaluation by the INSERM scientific committee CSS2 (Cancer), INSERM U935 has been renewed as a monothematic Inserm Unit UMRS 1310 under the direction of Pr. Ali Turhan. The Unit, in close collaboration with CITHERA is developing...
UMS45 CiTHERA – 28 rue Henri Desbruères 91100 Corbeil-Essonnes